Kim Kim RD RD First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Cancer Discov Cancer Discov 2019 2019 9 9 1696 1696 1707 1707 supplied-pmid 31575541? Here, FGF19 is linked to hepatocellular carcinoma.